Safety of eribulin: A real-world study based on a pharmacovigilance database
{"Eribulin":[0],"is":[1],"used":[2],"to":[3,25,153,174],"treat":[4],"metastatic":[5],"breast":[6],"cancer,":[7],"but":[8],"its":[9],"adverse":[10,157,167],"event":[11],"(AE)":[12],"profile":[13],"requires":[14,150],"comprehensive":[15],"analysis":[16],"using":[17],"FDA":[18],"Adverse":[19],"Event":[20],"Reporting":[21],"System":[22],"(FAERS)":[23],"data":[24],"guide":[26],"clinical":[27],"use.":[28],"We":[29],"analyzed":[30],"eribulin-related":[31],"AE":[32,49,55,71],"reports":[33,56],"in":[34,132,171],"FAERS":[35,66],"(Q1":[36],"2011":[37],"-":[38],"Q2":[39],"2024).":[40],"Disproportionality":[41],"analyses":[42],"(ROR,":[43],"PRR,":[44],"MGPS,":[45],"BCPNN)":[46],"identified":[47],"significant":[48],"signals.":[50],"Our":[51],"study":[52],"finalized":[53],"3570":[54],"with":[57],"eribulin":[58,149],"as":[59,138,159,161],"the":[60,65,107,172],"primary":[61],"suspect":[62],"drug":[63,133],"from":[64],"database,":[67],"including":[68],"7455":[69],"coded":[70],"records.":[72],"The":[73],"included":[74,119],"patients":[75],"were":[76,135],"predominantly":[77],"female":[78],"(90.1%)":[79],"and":[80,93,123,143,155,164],"aged":[81],"35-59":[82],"years":[83],"(42.61%).":[84],"Eribulin-associated":[85],"AEs":[86,118,128],"spanned":[87],"26":[88],"organ":[89],"systems.":[90],"Only":[91],"\\"Blood":[92],"lymphatic":[94,156],"system":[95],"disorders\\"":[96],"(n":[97],"=":[98],"1,788)":[99],"met":[100],"significance":[101],"across":[102],"all":[103],"four":[104],"algorithms.":[105],"At":[106],"preferred":[108],"term":[109],"level,":[110],"95":[111],"positive":[112],"disproportionality":[113],"signals":[114],"emerged.":[115],"Common":[116],"expected":[117],"neutropenia,":[120,122],"febrile":[121],"leukopenia.":[124],"Critically,":[125],"serious":[126,176],"unexpected":[127],"not":[129,169],"consistently":[130],"referenced":[131],"inserts":[134],"identified,":[136],"such":[137],"pleural":[139],"effusion,":[140],"respiratory":[141],"failure,":[142],"cardiac":[144],"failure.":[145],"Clinical":[146],"use":[147],"of":[148,166],"great":[151],"attention":[152],"blood":[154],"events,":[158],"well":[160],"enhanced":[162],"monitoring":[163],"reporting":[165],"events":[168],"mentioned":[170],"insert":[173],"prevent":[175],"AEs.":[177]}
Authors
- Anqi Ge (ORCID: https://orcid.org/0000-0001-7193-8985)
- Jie Gong (ORCID: https://orcid.org/0000-0002-3923-2488)
- Shiting Wu (ORCID: https://orcid.org/0000-0002-3878-6526)
- Ruhong Zhou (ORCID: https://orcid.org/0000-0001-8624-5591)
- Lele Shen
- Lin Qi (ORCID: https://orcid.org/0000-0001-7398-327X)
- Jie Ling
- Lifang Liu (ORCID: https://orcid.org/0009-0004-4274-4515)
Institutions
- First Affiliated Hospital of Hunan University of Traditional Chinese Medicine (CN)
- Hunan Academy of Traditional Chinese Medicine (CN)
- Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-09-17
- DOI
- https://doi.org/10.1371/journal.pone.0356800
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00